Tag: MDS

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Onclive8

Immunotherapy Inches Forward in Development of Myeloid Malignancies

Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.

Visit website
vjhemonic11

Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting.

Visit website
vjhemonic17

Current immune checkpoint inhibitor trials in AML/MDS

  Dec 07 2020 Tagged ICI, AML, MDS

Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, discusses several current trials of immune checkpoint inhibition in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) that were presented at ASH 2020.

Visit website
Immunotherapy Web Featured Images 46

ASH 2020 | Phase I trial of decitabine plus ipilimumab in R/R MDS & AML

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase I trial (NCT02890329) of decitabine (DAC) in combination with ipilimumab (IPI) in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), with or without prior allogeneic hematopoietic cell transplantation (allo-HCT).

Visit website